1. Bivalirudin as an anticoagulant for simultaneous integrated coronary artery revascularization - a novel approach to an inherent concern.
- Author
-
McClure RS, Higgins J, Swinamer SA, Rayman R, Dobkowski WB, Kostuk WJ, and Kiaii B
- Subjects
- Coronary Artery Disease diagnosis, Hirudins, Humans, Male, Middle Aged, Recombinant Proteins therapeutic use, Anticoagulants therapeutic use, Coronary Artery Disease drug therapy, Coronary Vessels, Myocardial Revascularization, Peptide Fragments therapeutic use
- Abstract
Background: Simultaneous integrated coronary artery revascularization combines coronary artery bypass surgery and percutaneous coronary intervention into a single procedure. This approach provides immediate, complete and optimal myocardial revascularization in a less invasive manner. Because simultaneous integrated coronary revascularization necessitates two distinct anticoagulation protocols for the surgical and percutaneous aspects of the procedure, combining these anticoagulation protocols carries a bleeding risk. Using a single anticoagulant to facilitate the necessities of both aspects of the integrated approach may alleviate this risk., Case Presentation: A 45-year-old man with an occluded left anterior descending artery and a moderately stenotic circumflex artery underwent simultaneous integrated coronary revascularization. Bivalirudin was used to achieve anticoagulation for the duration of the procedure. The patient was asymptomatic with excellent patency of both the bypass graft and the stented circumflex artery via angiography at 10 months., Conclusion: Bivalirudin can be used to effectively achieve a unified anticoagulation protocol for simultaneous integrated revascularization.
- Published
- 2009
- Full Text
- View/download PDF